Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 8/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racemoramide SCHEMBL25463 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| Levomoramide SCHEMBL907811 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| Racemoramide SCHEMBL7474188 | 0.98 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| Racemoramide SCHEMBL548433 | 0.94 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| SCHEMBL9917087 | 0.93 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| SCHEMBL9917086 | 0.88 | KDM4E (0.46) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| SCHEMBL22313199 | 0.88 | L3MBTL1 (0.52) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| Racemoramide SCHEMBL8741247 | 0.86 | ADRA2B (0.44) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| SCHEMBL17028079 | 0.86 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 | |
| SCHEMBL22313196 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1LMNANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 689 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240288374-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation | 2024-08-29 | — | — | US | claimed |
| WO-2024172892-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation (US) | 2024-08-22 | — | — | WO | claimed |
| US-20200345723-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | COLLEGIUM PHARMACEUTICAL INC (US) | 2020-11-05 | — | — | US | claimed |
| US-20200345722-A1 | ABUSE-DETERRENT DRUG FORMULATIONS | COLLEGIUM PHARMACEUTICAL INC (US) | 2020-11-05 | — | — | US | claimed |
| US-20200093819-A1 | ABUSE-DETERRENT DRUG FORMULATIONS | COLLEGIUM PHARMACEUTICAL, INC. | 2020-03-26 | — | — | US | claimed |
| US-20200093820-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2020-03-26 | — | — | US | claimed |
| EP-3560484-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2019-10-30 | — | — | EP | claimed |
| EP-3423034-B1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G L PHARMA GMBH (AT) | 2019-07-10 | — | — | EP | claimed |
| EP-3423034-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2019-01-09 | — | — | EP | claimed |
| CN-109069419-A | Abuse resistant drugs composition | G.L.制药有限责任公司 | 2018-12-21 | — | — | CN | claimed |
| US-20050281748-A1 | Abuse-deterrent drug formulations | COLLEGIUM PHARMACEUTICAL, INC. | 2005-12-22 | — | — | US | claimed |
| EP-1594467-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | Collegium Pharmaceutical, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| EP-1569925-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-07 | — | — | EP | claimed |
| WO-2004055003-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| US-20040052731-A1 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs | COLLEGIUM PHARMACEUTICALS, INC. | 2004-03-18 | — | — | US | claimed |
| WO-2004004693-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIODS AND OTHER DRUGS | COLLGEGIUM PHARMACEUTICAL (US) | 2004-01-15 | — | — | WO | claimed |
| EP-0608893-B1 | Compositions for inhibiting the development of tolerance to and/or dependence on an additive substance | UNIV VIRGINIA COMMONWEALTH (US) | 2001-12-12 | — | — | EP | claimed |
| US-5654281-A | Inhibiting the development of tolerance to and/or dependence on an addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1997-08-05 | — | — | US | claimed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |